Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J0750
200 mg/300 mg
Medicare payment limit per unit (Q4 2026): $0.451
No published MUE for J0750. CMS keeps some MUE values confidential, so this does not mean there is no daily unit limit.
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.451per 200 mg/300 mg
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 0.000%
CMS note: “HIV PrEP drug”
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.451 | 200 mg/300 mg | 0% | −0.4% | HIV PrEP drug |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.453 | 200 mg/300 mg | 0% | −7.2% | HIV PrEP drug |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.488 | 200 mg/300 mg | 0% | −63.6% | HIV PrEP drug |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.342 | 200 mg/300 mg |
Medicare hospital outpatient (OPPS) · Q4 2026
K Paid separately (non-pass-through drug or biological)
$0.451 per unit · APC 0806 · copayment $0.000 per unit
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 50090-6494-01 | Emtricitabine/Tenofovir disoproxil fumarateA-S Medication Solutions | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 50090-7719-01 | Emtricitabine/Tenofovir disoproxil fumarateA-S Medication Solutions | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q2 2026 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 60687-0719-25 | Emtricitabine/Tenofovir disoproxil fumarateAmerican Health Packaging | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | Excluded listingEmtricitabine and Tenofovir Disoproxil Fumarate |
| 69238-2095-03 | Emtricitabine/Tenofovir disoproxil fumarateAmneal Pharmaceuticals LLC | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 65862-0354-30 | Emtricitabine/Tenofovir disoproxil fumarateAurobindo Pharma Limited | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 42291-0439-30 | Emtricitabine/Tenofovir disoproxil fumarateAvkare | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | Excluded listingEmtricitabine and Tenofovir Disoproxil Fumarate |
| 31722-0560-30 | Emtricitabine/Tenofovir disoproxil fumarateCamber Pharmaceuticals Inc. | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 69097-0741-02 | Emtricitabine/Tenofovir disoproxil fumarateCipla USA | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 76282-0677-30 | Emtricitabine/Tenofovir disoproxil fumarateExelan Pharmaceuticals Inc | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 61958-0701-01 | TruvadaGilead Sciences INC. | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedTruvada |
| 61958-0703-01 | TruvadaGilead Sciences INC. | 30 × 1 | 15 | 15 | $6.77 | PrEP | Q1 2025 – Q4 2026 | ListedTruvada |
| 61958-0704-01 | TruvadaGilead Sciences INC. | 30 × 1 | 20 | 20 | $9.02 | PrEP | Q1 2025 – Q4 2026 | ListedTruvada |
| 61958-0705-01 | TruvadaGilead Sciences INC. | 30 × 1 | 25 | 25 | $11.28 | PrEP | Q1 2025 – Q4 2026 | ListedTruvada |
| 51407-0112-30 | Emtricitabine/Tenofovir disoproxil fumarateGolden State Medical Supply Inc | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 42385-0953-30 | Emtricitabine/Tenofovir disoproxil fumarateLaurus Labs Limited | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 42385-0953-90 | Emtricitabine/Tenofovir disoproxil fumarateLaurus Labs Limited | 90 × 1 | 90 | 90 | $40.59 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 68180-0287-01 | Emtricitabine/Tenofovir disoproxil fumarateLupin Pharmaceuticals Inc | 100 × 1 | 100 | 100 | $45.10 | PrEP | Q4 2024 – Q4 2026 | Not found |
| 68180-0287-06 | Emtricitabine/Tenofovir disoproxil fumarateLupin Pharmaceuticals Inc | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | Not found |
| 33342-0106-07 | Emtricitabine/Tenofovir disoproxil fumarateMacLeods Pharmaceuticals Limited | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 00904-7172-07 | Emtricitabine/Tenofovir disoproxil fumarateMajor Pharmaceuticals | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 00378-1930-93 | Emtricitabine/Tenofovir disoproxil fumarateMylan Pharmaceuticals Inc. | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | Excluded listingEmtricitabine and Tenofovir Disoproxil Fumarate |
| 16714-0534-01 | Emtricitabine/Tenofovir disoproxil fumarateNorthstar RxLLC | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 54868-5141-00 | TruvadaPhysicians Total Care Inc | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | Excluded listingTruvada |
| 71205-0776-30 | Emtricitabine/Tenofovir disoproxil fumarateProficient Rx LP | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 71205-0776-60 | Emtricitabine/Tenofovir disoproxil fumarateProficient Rx LP | 60 × 1 | 60 | 60 | $27.06 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 71205-0776-90 | Emtricitabine/Tenofovir disoproxil fumarateProficient Rx LP | 90 × 1 | 90 | 90 | $40.59 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 82009-0109-30 | Emtricitabine/Tenofovir disoproxil fumarateQuallent Pharmaceuticals LLC | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 42543-0719-04 | Emtricitabine/Tenofovir disoproxil fumarateStrides Pharma Inc | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 64380-0719-04 | Emtricitabine/Tenofovir disoproxil fumarateStrides Pharma Science Limited | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 00093-7704-56 | Emtricitabine/Tenofovir disoproxil fumarateTeva Pharmaceuticals | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 70710-1367-03 | Emtricitabine/Tenofovir disoproxil fumarateZydus Pharmaceuticals USA | 30 × 1 | 30 | 30 | $13.53 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 70710-1367-04 | Emtricitabine/Tenofovir disoproxil fumarateZydus Pharmaceuticals USA | 100 × 1 | 100 | 100 | $45.10 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
| 70710-1367-09 | Emtricitabine/Tenofovir disoproxil fumarateZydus Pharmaceuticals USA | 90 × 1 | 90 | 90 | $40.59 | PrEP | Q4 2024 – Q4 2026 | ListedEmtricitabine and Tenofovir Disoproxil Fumarate |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 60505-4202-03 | Emtricitabine/Tenofovir disoproxil fumarateApotex | 30 × 1 | 30 | 30 | PrEP | Q1 2025Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2025 | Dates changed | N — No maintenance | Added Jan 2, 2024 · action effective Jan 1, 2025 · termination — |
| Q1 2024 | Added to HCPCS | A — Added | Added date Jan 2, 2024 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| 0% |
| −22.6% |
| HIV PrEP drug |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.734 | 200 mg/300 mg | 0% | −0.1% | HIV PrEP drug |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.736 | 200 mg/300 mg | 0% | +35.9% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.277 | 200 mg/300 mg | 0% | −29.7% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $1.817 | 200 mg/300 mg | 0% | — | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | N/A | 200 mg/300 mg | 0% | — | The payment allowance for this code will be determined by the MAC processing the claim. |
|---|